Kura Oncology (NASDAQ:KURA) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.
Several other equities analysts have also recently issued reports on KURA. Oppenheimer set a $18.00 price target on Kura Oncology and gave the company a “buy” rating in a research report on Thursday, November 16th. ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cann reaffirmed a “buy” rating and issued a $17.50 price objective on shares of Kura Oncology in a report on Monday, December 11th. Wedbush started coverage on Kura Oncology in a report on Wednesday, December 20th. They issued an “outperform” rating and a $19.00 price objective on the stock. Finally, Zacks Investment Research lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Kura Oncology presently has an average rating of “Buy” and a consensus target price of $21.67.
Kura Oncology (NASDAQ KURA) opened at $19.95 on Friday. The stock has a market capitalization of $753.80, a PE ratio of -12.95 and a beta of 4.10. Kura Oncology has a 52-week low of $5.90 and a 52-week high of $24.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 13.48.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01). equities analysts expect that Kura Oncology will post -1.58 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in KURA. New York State Common Retirement Fund purchased a new stake in Kura Oncology in the 2nd quarter valued at approximately $142,000. MetLife Investment Advisors LLC purchased a new stake in Kura Oncology in the 4th quarter valued at approximately $155,000. American International Group Inc. boosted its holdings in Kura Oncology by 42.0% in the 4th quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after purchasing an additional 4,012 shares in the last quarter. California State Teachers Retirement System purchased a new stake in Kura Oncology in the 2nd quarter valued at approximately $235,000. Finally, Teachers Advisors LLC purchased a new stake in Kura Oncology in the 2nd quarter valued at approximately $256,000. 64.65% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/16/kura-oncology-kura-downgraded-by-bidaskclub-to-buy.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.